 Home > Medical News > Latest Medical News > The multi-target inhibitor introduced by Zai Lab over US$350 million received clinical approval for the first time

The multi-target inhibitor introduced by Zai Lab over US$350 million received clinical approval for the first time

 Last Update: 2022-01-14
 Source: Internet
 Author: User

Tags

wax drug

spectra 1 2

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Article source: Medical Rubik's Cube Info

Author: Sunshine

On November 23, the CDE official website showed that Turning Point's TPX-0022 capsule clinical trial application was approved by the Food and Drug Administration for the treatment of locally advanced or metastatic non-small cell lung cancer, gastric cancer or solid tumors with MET gene mutations

TPX-0022 is an oral multi-target kinase inhibitor targeting MET and related cancer signaling pathways SRC and CSF1R

MET is a tyrosine kinase receptor for hepatocyte growth factor (HGF).

TPX-0022 (elzovantinib) has a new three-dimensional macrocyclic structure that can inhibit MET, CSF1R (colony stimulating factor 1 receptor) and SRC kinase, and has the potential to regulate the tumor microenvironment to enhance its therapeutic effect

In October 2021, Turning Point announced the latest clinical data for the dose exploration part of the Phase I SHIELD-1 study

In response to feedback from the FDA, Turning Point plans to initiate the phase II part of the SHIELD-1 study, and at the same time to initiate the phase Ib/II SHIELD-2 study in combination with epidermal growth factor receptor (EGFR) targeted therapy in mid-2022 (see The new drug clinical research application (IND) will be approved by the FDA depending on the time)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.